tradingkey.logo

Aclaris Therapeutics Inc <ACRS.OQ> expected to post a loss of 12 cents a share - Earnings Preview

ReutersMay 2, 2025 11:27 AM
  • Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to show a fall in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025

  • The Wayne Pennsylvania-based company is expected to report a 46.6% decrease in revenue to $1.28 million from $2.4 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aclaris Therapeutics Inc is for a loss of 12 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00​, above​ its last closing price of $1.38. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.20

-0.22

-1.01

Missed

-362.1

Sep. 30 2024

0.04

-0.01

-0.11

Missed

-1,826.4

Jun. 30 2024

-0.20

-0.20

-0.15

Beat

26.6​

Mar. 31 2024

-0.26

-0.29

-0.24

Beat

16

​​Dec. 31 2023

-0.33

-0.34

-0.02

Beat

94.2

Sep. 30 2023

-0.47

-0.48

-0.41

Beat

14.6​

Jun. 30 2023

-0.44

-0.45

-0.42

Beat

6.7

Mar. 31 2023

-0.43

-0.44

-0.40

Beat

8.6

This summary was machine generated May 2 at 11:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI